TABLE I.
Clinical characteristics of the study population
| Characteristic | Value |
|---|---|
| Sex, n (%) | |
| Women | 41 (68) |
| Men | 19 (32) |
| Age (y) | |
| Mean (SD; SEM) | 50.1 (17.0; 2.2) |
| Median (min; max) | 51.5 (17; 82) |
| BMI (kg/m2), mean | 30.0 |
| Race/ethnicity, n (%) | |
| White/Non-Hispanic | 50 (83) |
| White/Hispanic | 4 (7) |
| Asian | 4 (7) |
| Other | 2 (3) |
| Atopic by skin testing or specific IgE, n (%)* | |
| Yes | 30 (79) |
| No | 8 (21) |
| Maintenance inhaler at study enrollment, n (%) | |
| ICS | 18 (30) |
| ICS/LABA | 39 (65) |
| None or refused | 3 (5) |
| FEV1 % predicted within 6 mo of study enrollment, n (%)* | |
| <60% predicted | 5 (14) |
| 60%–80% predicted | 11 (31) |
| >80% predicted | 19 (54) |
| Patients receiving systemic corticosteroids in the last | 24 (40) |
| 6 mo before enrollment, n (%) | |
| ACT score at study enrollment | |
| Mean ± SD | 16.6 ± 4.6 |
| Median (min; max) | 17 (5; 24) |
| Red: score <16, n (%) | 24 (40) |
| Yellow: score 16–19, n (%) | 17 (28) |
| Green: score >19, n (%) | 19 (32) |
BMI, Body mass index; FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; IgE, immunoglobulin E; LABA, long-acting beta-agonist; SEM, standard error of mean.
*
Atopy status and spirometry results were not available by retrospective chart review for the entire study population.